Home » Celator Pharmaceuticals, the Leukemia & Lymphoma Society Announce Positive Data from Phase IIb Study of CPX-351
Celator Pharmaceuticals, the Leukemia & Lymphoma Society Announce Positive Data from Phase IIb Study of CPX-351
Celator Pharmaceuticals announced positive clinical data in first relapse patients with acute myeloid leukemia treated with CPX-351 (cytarabine:Daunorubicin) Liposome Injection.
MarketWatch
MarketWatch
Upcoming Events
-
07May
-
14May
-
30May